Viewing nowCombinationZadis Duo Sustained Release Tablet 10/1000 mg (Empagliflozin, Metformin)
Empagliflozin 10mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.

MFDS item code 202501247 · Approved 2025.05.21 · Insurance code 657808420
Improvement of blood glucose control in adults with type 2 diabetes mellitus
This medication is used to improve blood sugar control in adults with type 2 diabetes, in conjunction with dietary and exercise regimens, by combining empagliflozin and metformin. It is particularly suitable for patients whose blood sugar is not adequately controlled, and those with cardiovascular disease should refer to the related precautions. Thus, this medication effectively aids in managing blood sugar in type 2 diabetes patients and contributes to improving their health.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Take one tablet of this drug 10/1000 mg extended-release tablet or 25/1000 mg extended-release tablet once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To preserve its extended-release properties, this drug should be swallowed whole and not split, crushed, ground, or chewed. ⦁ When this drug is taken by patients who cannot achieve adequate glycemic control with metformin alone or in combination with other drugs such as insulin, the recommended initial total daily dose is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from combination therapy with empagliflozin and metformin to this drug should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. ⦁ When this drug is coadministered with a sulfonylurea or insulin, a dose reduction of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. As dosage adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60 mL/min/1.73m2], if the drug is well tolerated and there are no other conditions that may increase the risk of lactic acidosis, it may be used with adjustment of the metformin hydrochloride dose as follows. - Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, this drug should be discontinued immediately. In patients aged 75 years or older, renal function and the risk of volume depletion should be considered.
This medication is an antidiabetic agent that helps control blood sugar levels. However, there are several precautions to be taken when using this drug. First, due to the presence of metformin, there is a rare risk of lactic acidosis, a serious side effect that should be reported to a doctor immediately if suspected. Additionally, co-administration with insulin or sulfonylureas may result in hypoglycemia, so caution is required. Patients with impaired kidney function, acute infections, dehydration, and certain diseases such as heart failure should not take this medication. It should be discontinued before tests or surgeries involving iodinated contrast agents and resumed only after kidney function has normalized. This medication may increase urine output, causing fluid loss, thus special caution is needed for patients at risk of dehydration or the elderly. During treatment, urinary tract infections or genital infections may occur, and if symptoms appear, immediate treatment is required. Vitamin B12 levels may decrease, so regular monitoring is advisable. Alcohol consumption can increase the risk of lactic acidosis, thus excessive drinking should be avoided during treatment. It is recommended that pregnant or breastfeeding women do not use this medication. Additionally, this medication should be swallowed whole without chewing or crushing, and it is normal for the tablet shell to appear in the stool. While taking this medication, blood sugar levels and kidney function should be monitored regularly, and any abnormal symptoms should be discussed with healthcare providers.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. Furthermore, it should be stored at room temperature between 1°C and 30°C, away from extreme heat or cold.
Yellow oblong sustained-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationEmpagliflozin 10mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.